A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.
Innate swaps its lead candidate for Astra’s Lumoxiti in a bid to become a rare cancer player.
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Eisai deal to help Merck expand checkpoint inhibitor franchise.